Walter M. Stadler to Quinolones
This is a "connection" page, showing publications Walter M. Stadler has written about Quinolones.
Connection Strength
0.200
-
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.
Score: 0.119
-
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol. 2014 Nov; 32(8):1308-16.
Score: 0.029
-
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Dec 15; 19(24):6891-901.
Score: 0.028
-
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20; 29(30):4022-8.
Score: 0.024